The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

LIX.e

Pneumocystis jiroveci pneumonia

Publications

Abkur TM, Saeed M, Ahmed SZ, McArthur R, Leahy M, O'Leary H, O'Keeffe D

Pneumocystis jiroveci prophylaxis in patients undergoing Bendamustine treatment: the need for a standardized protocol.

Clinical case reports 2015 Apr;3;255-9 — 2015 Apr — 255-9

Carter SJ, Bernstein SH, Friedberg JW, Barr PM

Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma.

Leukemia research 2011 Nov;35;e223-4 — 2011 Nov — e223-4

Klippstein A, Schneider CP, Sayer HG, Höffken K

Pneumocystis carinii pneumonia as a complication of bendamustine monotherapy in a patient with advanced progressive breast cancer.

Journal of cancer research and clinical oncology 2003 May;129;316-9 — 2003 May — 316-9